Albumin Binding Immunomodulatory Compositions


The invention relates to molecules wherein Evan’s Blue dye is chemically conjugated to CpG Oligonucleotides that elicit anti-tumoral or infection fighting immunity. Evans Blue, a symmetric azo dye, has high binding affinity to albumin. Albumin binding ability of Evans blue is utilized with CpGs and tumor-specific antigens, in order to leverage endogenous albumin that increases the safety and the potency of molecular vaccines. As such, the molecular entities provided here enable efficient delivery and prolonged retention in lymph nodes and reduce systemic toxicity of Evans Blue and enhanced the therapeutic potency of molecular vaccines.

Potential Commercial Applications: Competitive Advantages:
  • Cancer therapeutics
  • Infectious disease therapeutics
  • Lymph node specificity
  • Higher stability/Lower toxicity
 


Development Stage:
Early-stage

Inventors:

Xiaoyuan Chen (NIBIB)  ➽ more inventions...

Guizhi Zhu (NIBIB)  ➽ more inventions...


Intellectual Property:
US Application No. 62/331,890
PCT Application No. PCT/US2017/031098
US Application No. 16/098,115

Licensing Contact:
Michael Davis, Ph.D., J.D.
Email: michael.davis4@nih.gov
Phone: 301-451-9032

OTT Reference No: E-149-2016-0
Updated: Jun 22, 2016